Lecia V. Sequist on Side Effects From Agents for Resistant Lung Cancer

Article

Lecia V. Sequist, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291).

Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291), two agents specific to acquired T790M mutations in EGFR-positive non-small cell lung cancer (NSCLC).

Related Videos
Dr. Mikhael in an interview with CURE
Dr. Hanna in an interview with CURE
Dr. Manisha Thakuria in an interview with CURE
Dr. Beth Goldstein in an interview with CURE
D'Agostino in an interview with CURE
Dr. Chapman-Davis in an interview with CURE
Dr. Psutka in an interview with CURE
Dr. Nitin Ohri in an interview with CURE
Dr. Ngwa in an interview with CURE
Related Content